deltatrials
Completed PHASE2 NCT00768859

Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study

Sponsor: The Netherlands Cancer Institute

Conditions Breast Cancer HER2 Positive
Interventions paclitaxel, trastuzumab and carboplatin
Updated 5 times since 2017 Last updated: May 10, 2012 Started: Sep 30, 2008 Primary completion: Aug 31, 2011 Completion: May 31, 2012

A PHASE2 clinical study on Breast Cancer and HER2 Positive, this trial is completed. The trial is conducted by The Netherlands Cancer Institute and has accumulated 5 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The Netherlands Cancer Institute
Data source: The Netherlands Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Alkmaar, Netherlands
  • • Amsterdam, Netherlands
  • • Delft, Netherlands
  • • Eindhoven, Netherlands
  • • Haarlem, Netherlands
  • • Leiden, Netherlands
  • • Leidschendam, Netherlands
  • • Nieuwegein, Netherlands